Supplementary Table 1. Key baseline measures

Supplementary table 1. Key baseline measures

Parameter	Overall (n=56)	Dapagliflozin (n=28)	Placebo (n=28)	p value
	Mean (SD)	Mean (SD)	Mean (SD)	
Age (years)	67.1 (6.9)	66.9 (7.0)	67.4 (6.8)	0.788
Male gender	37 (66.1%)	18 (64.3%)	19 (67.9%)	0.054
Weight (kg)	91.5 (18.6)	92.9 (18.1)	90.2 (19.3)	0.587
BMI (kg/m2)	32.5 (5.3)	33.0 (5.5)	32 (5.2)	0.495
Functional Class:				
NYHA I	25 (44.6%)	12 (42.9%)	13 (46.4%)	0.794
NYHA II	24 (42.9%)	13 (46.4%)	11 (39.3%)	0.546
NYHA III	7 (12.5%)	3 (10.7%)	4 (14.3%)	0.245
Blood pressure / Heart Rate:				
SBP (mmHg)	133.9 (17.1)	135 (15.4)	132.8 (18.8)	0.627
DBP (mmHg)	72.7 (10.0)	74 (7.1)	71.4 (12.2)	0.328
MAP (mmHg)	93.1 (10.4)	94.4 (7.3)	91.9 (12.8)	0.373
HR (bpm)	76.0 (12.8)	77.6 (14.0)	74.4 (11.6)	0.354
Etiology of heart failure:				
IHD	30 (53.6%)	15 (53.6%)	15 (53.6%)	0.845
DCM	13 (23.2%)	7 (25.0%)	6 (21.4%)	0.456
Other	11 (19.6%)	5 (17.9%)	6 (21.4%)	0.124
Unknown	2 (3.6%)	1 (3.6%)	1 (3.6%)	1

Duration of disease:				
Heart failure (years)	**6.24 (6.49)**	**6.64 (6.1)**	**5.83 (6.99)**	**0.649**
Type 2 diabetes (years)	**8.77 (6.26)**	**8.41 (6.5)**	**9.14 (6.17)**	**0.672**
Co-morbidities:				
Hypertension	**40 (71.4%)**	**22 (78.6%)**	**18 (64.3%)**	**0.485**
AF	**22 (39.3%)**	**11 (39.3%)**	**11 (39.3%)**	**0.998**
PAD	**9 (16.1%)**	**5 (17.9%)**	**4 (14.3%)**	**0.842**
Stroke / TIA	**10 (17.9%)**	**3 (10.7%)**	**7 (25.0%)**	**0.06**
MI	**29 (51.8%)**	**14 (50.0%)**	**15 (53.6%)**	**0.475**
Medications:				
Loop diuretic dose (mg)*	**49.8 (22.0)**	**52.9 (20.5)**	**46.8 (23.4)**	**0.307**
ACE-I/ARB	**50 (89.3%)**	**25 (89.3%)**	**25 (89.3%)**	**0.985**
Beta blockers	**46 (82.1%)**	**24 (85.7%)**	**22 (78.6%)**	**0.877**
MRA	**23 (41.1%)**	**13 (46.4%)**	**10 (35.7%)**	**0.898**
Metformin	**31 (55.4%)**	**17 (60.7%)**	**14 (50.0%)**	**0.978**
Other OHA	**22 (39.3%)**	**13 (46.4%)**	**9 (32.1%)**	**0.413**
Insulin	**16 (28.6%)**	**6 (21.4%)**	**10 (35.7%)**	**0.657**
Cardiac MRI Parameters:				
LVESV† (ml)	**102.7 (50.5)**	**99.2 (40.7)**	**106.4 (59.6)**	**0.604**

Indexed LVESV† (ml/m2)	**51.6 (26.2)**	**49.4 (21.3)**	**54.1 (30.9)**	**0.52**
LVEDV † (ml)	**180.2 (61.0)**	**172.4 (47.7)**	**188.3 (72.4)**	**0.346**
Indexed LVEDV† (ml/m2)	**90.3 (30.9)**	**85.9 (24.1)**	**95.0 (36.8)**	**0.294**
LVEF† (%)	**45.5 (12.0)**	**44.5 (12.4)**	**46.5 (11.7)**	**0.526**
LV Mass Index† (g/m2)	**71.5 (17.7)**	**69.5 (16.3)**	**73.7 (19.3)**	**0.398**
LV Stroke Vol† (ml)	**38.7 (10.4)**	**36.6 (10.4)**	**41 (10.2)**	**0.126**
Indexed LA Volume††(ml/m2)	**50.0 (18.9)**	**49.0 (18.8)**	**51 (19.3)**	**0.699**
Biochemistry:				
Hb (g/dL)	**13.5 (1.6)**	**13.2 (1.3)**	**13.8 (1.5)**	**0.294**
Hct (%)	**40.9 (4.7)**	**40.4 (3.9)**	**41.4 (5.4)**	**0.405**
HbA1c (mmol/mol)	**60.9 (17.1)**	**63.0 (17.8)**	**58.6 (16.4)**	**0.339**
BHB (mmol/L)	**0.2 (0.1)**	**0.2 (0.1)**	**0.2 (0.1)**	**0.865**
Creatinine (µmol/L)	**88.2 (19.9)**	**92.0 (19.9)**	**84.4 (19.5)**	**0.151**
eGFR (ml/min/1.73m2)	**72.0 (19.2)**	**67.7 (16.4)**	**76.2 (21.0)**	**0.254**

Abbreviations: Med=Median; SD=Standard deviation; IQR=Interquartile range; CI=Confidence interval; NS=Not significant; BMI=body mass index; NYHA=New York Heart Association functional classification for heart failure; SBP= systolic blood pressure; DBP=Diastolic blood pressure; MAP=Mean arterial pressure; IHD=Ischemic heart disease; HR=Heart Rate; bpm=beats per minute; DCM=Dilated cardiomyopathy; AF=Atrial fibrillation; PAD=Peripheral arterial disease; TIA=Transient ischemic attack; MI=Myocardial infarction; ACE-

SUPPLEMENTARY DATA

I=Angiotensin converting enzyme inhibitor; ARB=Angiotensin receptor blocker; MRA=Mineralocorticoid receptor antagonist; OHA=Oral hypoglycemic agent; LVEDV=Left ventricular end diastolic volume; LVESV=Left ventricular end systolic volume; LVEF=Left ventricular ejection fraction; LV=Left ventricular; Hb=Hemoglobin; Hct=Hematocrit; HbA1c=Hemoglobin A1c; eGFR=Estimated glomerular filtration rate; NT-proBNP=N-terminal pro B-type natriuretic peptide; hsCRP=High sensitivity C-reactive protein; Oxi-LDL=Oxidized low density lipoprotein; Na=Sodium; Alb=Albumin; ACR=Albumin:creatinine ratio; V02 Max=Peak oxygen consumption; VC02 Max=Peak carbon dioxide production; Ve=minute ventilation; Ve/VCO2= peak minute ventilation to carbon dioxide ratio; SF-36 PCS=Physical component summary of the short from 36; SF-36 MCS=Mental component summary of the short from 36; MLHF=Minnesota living with heart failure.

* Bumetanide dose converted to equivalent furosemide dose (1mg bumetanide = 40mg furosemide)
† = Unable to analyse baseline images of one participant in placebo group due to very poor image quality
†† = Unable to analyze baseline LA volume in 5 patients due to poor image quality (overall n= 51, dapagliflozin n=26, placebo n=25)
‡=Analysis excludes 2 patients in placebo arm who were unable to complete CPET